前列腺癌放疗期间微生物组与代谢组的动态变化
这项前瞻性研究纳入50例接受前列腺(床)仅照射(PBRT,n=28)或全盆腔照射(WPRT,n=22)的前列腺癌患者,纵向采集粪便样本,用16S rRNA基因测序和超高效液相色谱-高分辨质谱分析微生物组与代谢组;结果显示微生物α多样性随时间无显著变化,β多样性随治疗显著变化(PERMANOVA P=0.03),PBRT与WPRT间稳定性无显著差异,未建立与毒性状态相关的特征。
要点
- 放疗期间微生物α多样性无显著变化,β多样性随治疗显著变化(PERMANOVA P=0.03)。
- PBRT与WPRT比较,微生物组稳定性无显著差异。
- 基于代谢指纹未实现按毒性特征的自然聚类,未建立毒性状态特征。
核心结论
- 放射剂量和治疗体积对微生物组和代谢组指纹的影响有限。
- 未能建立与毒性状态相关的特征。
- 当前证据提示将代谢和微生物生物标志物转化为常规临床实践仍具挑战性。
研究设计与样本
- 前瞻性研究,纳入50例接受放疗的前列腺癌患者,其中前列腺(床)仅放疗(PBRT)28例、全盆腔放疗(WPRT)22例(NCT04638049)。
- 在放疗前、10次分次后、放疗接近结束时和随访时进行纵向采样。
- 患者症状二分为单一毒性评分;微生物组和代谢组分别通过16S rRNA基因测序和超高效液相色谱-高分辨质谱分析。
主要发现
- 个体α多样性随时间无显著变化。
- 微生物群组成(β多样性)随治疗显著变化(PERMANOVA P=0.03)。
- PBRT与WPRT比较,稳定性无显著差异。
- 放疗期间多种代谢物水平显著改变。
- 基线α多样性与任何毒性结局均无关联;基于代谢指纹未实现按毒性特征的自然聚类。
临床怎么用
- 原文未据此给出推荐。
局限性
- 当前证据提示将代谢和微生物生物标志物转化为常规临床实践仍具挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer patients treated with radiotherapy are susceptible to acute gastrointestinal (GI) toxicity due to substantial overlap of the intestines with the radiation volume. Due to their intimate relationship with GI toxicity, faecal microbiome and metabolome dynamics during radiotherapy were investigated. MATERIAL & METHODS: This prospective study included 50 prostate cancer patients treated with prostate (bed) only radiotherapy (PBRT) (n = 28) or whole pelvis radiotherapy (WPRT) (n = 22) (NCT04638049). Longitudinal sampling was performed prior to radiotherapy, after 10 fractions, near the end of radiotherapy and at follow-up. Patient symptoms were dichotomized into a single toxicity score. Microbiome and metabolome fingerprints were analyzed by 16S rRNA gene sequencing and ultra-high-performance liquid chromatography hybrid high-resolution mass spectrometry, respectively. RESULTS: The individual α-diversity did not significantly change over time. Microbiota composition (β-diversity) changed significantly over treatment (PERMANOVA p-value = 0.03), but there was no significant difference in stability when comparing PBRT versus WPRT. Levels of various metabolites were significantly altered during radiotherapy. Baseline α-diversity was not associated with any toxicity outcome. Based on the metabolic fingerprint, no natural clustering according to toxicity profile could be achieved. CONCLUSIONS: Radiation dose and treatment volume demonstrated limited effects on microbiome and metabolome fingerprints. In addition, no distinctive signature for toxicity status could be established. There is an ongoing need for toxicity risk stratification tools for diagnostic and therapeutic purposes, but the current evidence implies that the translation of metabolic and microbial biomarkers into routine clinical practice remains challenging.
引用
- Danckaert W, Spaas M, Sundahl N, et al. Microbiome and metabolome dynamics during radiotherapy for prostate cancer. Radiother Oncol. 2023. PMID: 37827280. doi:10.1016/j.radonc.2023.109950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。